GSK drug bepirovirsen shows functional cure for hepatitis B in trials

In a significant advancement in hepatitis B treatment, GSK's investigational drug bepirovirsen has demonstrated functional cure rates of 19-20% in patients participating in two Phase 3 clinical trials. The trials involved over 1,800 participants across 29 countries and assessed the impact of bepirovirsen when added to standard antiviral therapies over a 24-week period. These findings were published in late August 2026, marking a potential breakthrough for those living with chronic hepatitis B, a virus that affects millions worldwide.

The historical context for this research emphasizes the challenges faced in finding effective treatments for hepatitis B, which has long been a public health concern. Traditional antiviral treatments have been effective in managing the virus but have not led to complete eradication or functional cure. Bepirovirsen, a novel therapeutic agent, operates through a unique mechanism that targets the virus at multiple stages, potentially disrupting its lifecycle and enabling the immune system to regain control over the infection.

On-the-ground implementation of these trials involved a diverse group of patients, allowing researchers to gather data across various demographics. The trials were designed with a rigorous methodology, ensuring that the results were both reliable and valid. Participants received treatment for 24 weeks, after which their health was monitored to assess the long-term effects of the drug. The data revealed that 233 of the 1,220 patients who received bepirovirsen had undetectable levels of HBV DNA and surface antigen six months post-treatment, compared to none in the placebo group.

The broader implications of these findings extend beyond individual patient outcomes. A functional cure for hepatitis B could alleviate the burden on healthcare systems, reduce the incidence of liver disease, and improve the quality of life for millions affected by this virus. The successful outcomes of these trials may also pave the way for further research into similar therapies, potentially leading to more breakthroughs in the treatment of viral infections.

Looking ahead, the future of bepirovirsen appears promising as it undergoes regulatory review in multiple countries. If approved, it could become a vital part of the treatment landscape for hepatitis B, offering hope to patients who have long awaited a functional cure. The results of these trials may also inspire further innovations in antiviral therapies, underscoring the ongoing need for research in this critical area of public health.